CBX2 and neoplasm: As the overexpression of CBX2 is closely correlated with a poor prognosis for tumours (Wheeler et al., 2018; Zeng et al., 2021; Del Gaudio et al., 2022), CBX2 is expected to be a potential promising therapeutic target for cancer gene therapy.